Retatrutide
Triple GLP-1/GIP/glucagon receptor agonist — next-generation metabolic research compound
Mechanism
What is Retatrutide?
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. It has shown significant weight loss results — up to 24% body weight reduction in Phase 2 trials.
🇺🇸 United States · FDA
Legal status
Retatrutide has not received FDA approval for any indication. Not a DEA scheduled substance. Available for research purposes only — not for human consumption.
This website is intended for research and educational purposes only. The information provided does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any condition. Peptides discussed on this site are not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before using any substance.
Full legal guide for United States →Frequently asked
Common questions
Is retatrutide FDA approved?
No — retatrutide is in Phase 3 clinical trials as of 2024 and has not yet received FDA approval. It is being developed by Eli Lilly and approval is anticipated if Phase 3 trials succeed.
Can I buy retatrutide in the US?
Research-grade retatrutide is available from research peptide vendors in the US. It is not available by prescription as it has not received FDA approval.
Where to source Retatrutide
Retatrutide in United States
We verify COA documentation and purity standards before listing any vendor.
Retatrutide in other markets